Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
guidance
Pharma
BMS accentuates the positive after Cobenfy trial flop
On the heels of a clinical setback for BMS' schizophrenia newcomer Cobenfy, the company has served up mixed results for 2025's first quarter.
Fraiser Kansteiner
Apr 24, 2025 11:31am
J&J lifts 2025 sales guidance despite looming tariff threat
Apr 15, 2025 11:55am
WuXi AppTec offers rosy 2025 guidance despite US-China tensions
Mar 18, 2025 4:30pm
JPM25: Moderna slashes costs, guidance amid poor vaccine sales
Jan 13, 2025 11:31am
EuroAPI suspends 2024 guidance amid Italian production deficits
Mar 15, 2024 11:12am
Pfizer's 2024 revenue forecast triggers drop in share price
Dec 13, 2023 11:11am
